Gossamer and Chiesi pull the plug on PAH drug collaboration
Gossamer and Chiesi pull the plug on PAH drug collaboration.
Gossamer Bio
Gossamer Bio is a small molecule pharma company covered in the openbionews harvest.
Company Info
Workforce & Restructuring Tracker
View Industry Layoff Tracker →77 roles (48%)Confirmed
Gossamer Bio cut 48% of its workforce (77 employees) to conserve cash after its pivotal Phase 3 PROSERA trial evaluating inhaled PDGFR/CSF1R/c-KIT inhibitor seralutinib in pulmonary arterial hypertension (PAH) missed its primary six-minute walk distance (6MWD) endpoint at Week 24 and partner Chiesi exited the collaboration.